Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults
Sponsor: Qingyuan Zhan
Summary
Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults. It predominantly affects young individuals, progresses rapidly, and is associated with a high incidence of respiratory failure and multiple organ dysfunction. At present, there is no effective antiviral therapy available in China, and the reported mortality rate ranges from 41.5% to 80%. How to effectively reduce the mortality of severe adenovirus pneumonia, on the basis of conventional supportive care, is crucial for improving the prognosis of critically ill patients and alleviating the burden on families and society. We are currently conducting an adaptive, randomized, open-label controlled trial aimed at reducing mortality in severe adenovirus pneumonia. The primary objective of this study is to evaluate the efficacy and safety of adjunctive corticosteroid therapy at different dosages, in addition to early standard supportive treatment, in lowering mortality among patients with severe adenovirus pneumonia.
Official title: An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Adenovirus Community-Acquired Pneumonia in Adults
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
262
Start Date
2026-02-01
Completion Date
2027-12-31
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
Saline (0.9%, sterile, for infusion)
Sailine as control
low dose Methylprednisolone
Methylprednisolone 0.5mg/kg ivgtt qd
Moderate dose Methylprednisolone
Methylprednisolone 1.0mg/kg ivgtt qd